Weight loss drug semaglutide takes on atrial fibrillation
NCT ID NCT06499857
First seen Nov 15, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This study tests whether semaglutide, a medication used for weight loss, can help control atrial fibrillation (AF) in overweight or obese adults. About 200 people aged 18-75 with AF and a BMI of 30 or higher will receive semaglutide alongside standard AF care. The goal is to see if the drug reduces AF episodes and improves heart health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Arizona College of Medicine- Phoenix
NOT_YET_RECRUITINGPhoenix, Arizona, 85004, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.